Rhythm Pharmaceuticals jumps 36.6% after its oral drug bivamelagon shows strong BMI and hunger reductions in a phase II study in acquired hypothalamic obesity.

Fintel reports that on July 7, 2025, Leerink Partners initiated coverage of Rhythm Pharmaceuticals (NasdaqGM:RYTM) with a ...

Rhythm Pharmaceuticals' potential first-in-class HO drug, strong pipeline, and limited competition offer blockbuster potential. Click to read why RYTM is a Buy.

Rhythm Pharma (RYTM) stock gains as the company's experimental therapy bivamelagon shows promise in Phase 2 trial for rare acquired hypothalamic obesity. Read more here.

Markets concluded the week with a notable shift in sentiment. After reaching record highs earlier, U.S. stocks closed lower on Friday, impacted by macroeconomic concerns.

Rhythm's bivamelagon cut BMI and hunger scores in Phase 2 trial for hypothalamic obesity, prompting plans to discuss Phase 3 ...

Presentations highlight clinically meaningful reductions in BMI in patients with acquired hypothalamic obesity – - Full data ...

Toronto-based producer Loukeman talks his new project Sd-2, sampling techniques and unconventional effects processing ...

Rhythm Pharmaceuticals' experimental drug helped patients with a rare form of obesity caused by brain damage cut weight in a small study, the drugmaker said on Monday, sending its shares 24% higher in ...

Rhythm Pharmaceuticals, Inc. (RYTM) shares rallied 36.6% in the last trading session to close at $89. This move can be attributable to notable volume with a higher number of shares being traded than ...

Shares of US biopharma Rhythm Pharmaceuticals rose 27.4% to $82.96 in early trading today, as it announced positive top-line ...